Suchergebnisse - "Sharpley, Faye A"

PubPharm (15)

1

Acquired haemophilia A diagnosed during pregnancy

enthalten in: Obstetric medicine | 2023

von Ejaz, A. | O'Doherty, C. | Sharpley, F. | +3

2

Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK

enthalten in: European journal of haematology | 2021

von Sharpley, F. | Manwani, R. | Petrie, A. | +10

3

Myeloma clinical outcomes following the first wave of COVID-19 : results from the Thames Valley Cancer Alliance (UK)

enthalten in: British journal of haematology | 2021

von Sharpley, F. | Larham, J. | Haines, A. | +12

4

Myeloma clinical outcomes following the first wave of COVID‐19 : results from the Thames Valley Cancer Alliance (UK)

enthalten in: British Journal of Haematology | 2021

von Sharpley, F. | Larham, J. | Haines, A. | +12

5

Myeloma care adaptations in the UK during SARS-CoV-2 pandemic : Challenges and measurable outcomes

enthalten in: European journal of haematology | 2020

von Djebbari, F. | Panitsas, F. | Sharpley, F. | +6

6

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria

enthalten in: Haematologica | 2020

von Sharpley, F. | Fontana, M. | Martinez-Naharro, A. | +8

7

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma

enthalten in: Leukemia & lymphoma | 2020

von Sharpley, F. | Djebbari, F. | Fourali, S. | +4

CommentIn: Leuk Lymphoma. 2020 Mar;61(3):504-506. - PMID 31975634

8

Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis

enthalten in: European journal of haematology | 2020

von Sharpley, F. | De-Silva, D. | Mahmood, S. | +9

9

Amyloidosis Diagnosed in Solid Organ Transplant Recipients

enthalten in: Transplantation | 2020

von Sharpley, F. | Fontana, M. | Gilbertson, J. | +12

CommentIn: Transplantation. 2021 Mar 1;105(3):e33-e34. - PMID 33617206

10

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

enthalten in: PloS one | 2020

von Djebbari, F. | Sharpley, F. | McLain-Smith, S. | +5